Ellen Broug
Keine laufenden Positionen mehr
Profil
Ellen Broug worked as Director-Alliance Management at PanGenetics BV, Board Secretary & Head-IP at Merus NV, Head-Scientific Documentation & Target Evaluation at Genmab BV, and Head-Intellectual Property at Hubrecht Institute.
Ehemalige bekannte Positionen von Ellen Broug
Unternehmen | Position | Ende |
---|---|---|
Hubrecht Institute
Hubrecht Institute BiotechnologyHealth Technology The Hubrecht Institute is a research institute that focuses on fundamental, multidisciplinary research on healthy and diseased cells, tissues, and organisms. The location of the private company is in Utrecht, Netherlands. The institute encompasses 23 research groups dedicated to this mission. | Corporate Officer/Principal | - |
PanGenetics BV
PanGenetics BV Miscellaneous Commercial ServicesCommercial Services PanGenetics BV researches and develops antibody-based therapeutic products. It specializes in taking antibodies at the late research stage through to clinical proof of concept. The firm’s advanced programs are PG102, a CD40 antagonist, and PG110, an anti-Nerve Growth Factor antibody for use in chronic pain. The company was founded by Mark de Boer and James W. Larrick in 1995 and is headquartered in Utrecht, the Netherlands. | Corporate Officer/Principal | - |
Genmab BV
Genmab BV Miscellaneous Commercial ServicesCommercial Services Part of Genmab A/S, Genmab BV operates as a non-profit association for domestic violence law. The company is based in Utrecht, Netherlands. | Corporate Officer/Principal | - |
MERUS N.V. | Unternehmenssekretär | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
MERUS N.V. | Health Technology |
Private Unternehmen | 3 |
---|---|
PanGenetics BV
PanGenetics BV Miscellaneous Commercial ServicesCommercial Services PanGenetics BV researches and develops antibody-based therapeutic products. It specializes in taking antibodies at the late research stage through to clinical proof of concept. The firm’s advanced programs are PG102, a CD40 antagonist, and PG110, an anti-Nerve Growth Factor antibody for use in chronic pain. The company was founded by Mark de Boer and James W. Larrick in 1995 and is headquartered in Utrecht, the Netherlands. | Commercial Services |
Genmab BV
Genmab BV Miscellaneous Commercial ServicesCommercial Services Part of Genmab A/S, Genmab BV operates as a non-profit association for domestic violence law. The company is based in Utrecht, Netherlands. | Commercial Services |
Hubrecht Institute
Hubrecht Institute BiotechnologyHealth Technology The Hubrecht Institute is a research institute that focuses on fundamental, multidisciplinary research on healthy and diseased cells, tissues, and organisms. The location of the private company is in Utrecht, Netherlands. The institute encompasses 23 research groups dedicated to this mission. | Health Technology |